Skip to NavigationSkip to content

Zynteglo

CHMP recommendation for bluebird bio's gene therapy in β-thalassaemia

Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, Zynteglo (autologous CD34+ cells encoding β-globin AT87Q gene), securing recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) ) in the treatment of transfusion-dependent β-thalassaemia (TDT).

Specifically, the recommendation referred to the treatment of the blood disorder in patients over 12 years of age who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches